Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients
A Bryant, I Nivison-Smith, ES Pillai, G Kennedy, A Kalff, D Ritchie, B George, M Hertzberg, S Patil, A Spencer, K Fay, P Cannell, L Berkahn, R Doocey, R Spearing, J Moore
Bone Marrow Transplantation | NATURE PUBLISHING GROUP | Published : 2014
This was an Australasian Bone Marrow Transplant Recipient Registry (ABMTRR)-based retrospective study assessing the outcome of Fludarabine Melphalan (FluMel) reduced-intensity conditioning between 1998 and 2008. Median follow-up was 3.4 years. There were 344 patients with a median age of 54 years (18-68). In all, 234 patients had myeloid malignancies, with AML (n=166) being the commonest indication. There were 110 lymphoid patients with non-hodgkins lymphoma (NHL) (n=64) the main indication. TRM at day 100 was 14% with no significant difference between the groups. OS and disease-free survival (DFS) were similar between myeloid and lymphoid patients (57 and 50% at 3 years, respectively). Ther..View full abstract
Andrew Spencer has received research support from Celgene, Janssen and Novartis. The remaining authors declare no conflict of interest.